Abivax (ABVX) remains 'Best Idea' at Guggenheim following FY25 update

March 24, 2026 10:45 AM

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $175.00 price target on Abivax (NASDAQ: ABVX)The analyst commented, "Key highlights ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found